Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine

Yuewen Gong

doi:10.1007/s11655-012-1062-6

Your Location：

Home >

Browse articles >

Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine

OriginalPaper | Updated：2021-08-27

- Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine
- Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine
- 中国结合医学杂志（英文版） 2012年18卷第4期页码：245-249
- Affiliations：
  
  Faculties of Pharmacy and Medicine, University of Manitoba, Manitoba,Canada
- Author bio：
- Funds：
  
  Supported by Program of International S&T Cooperation Project (No. 2011DFA31860)
- DOI：10.1007/s11655-012-1062-6
  中图分类号：
- 纸质出版日期：2012，
  
  网络出版日期：2012-3-30，
Scan for full text
Gong, Y. Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine., Chin. J. Integr. Med. 18, 245–249 (2012). https://doi.org/10.1007/s11655-012-1062-6

Yuewen Gong. Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine[J]. Chinese Journal of Integrative Medicine, 2012,18(4):245-249.
Gong, Y. Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine., Chin. J. Integr. Med. 18, 245–249 (2012). https://doi.org/10.1007/s11655-012-1062-6 DOI：

Yuewen Gong. Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine[J]. Chinese Journal of Integrative Medicine, 2012,18(4):245-249. DOI： 10.1007/s11655-012-1062-6.

摘要

Liver fibrosis and hepatocellular carcinoma (HCC) are emerging health problems worldwide. Number of death due to HCC was steadily increased during the last decade. Although liver fibrosis and HCC have been investigated extensively

there are no successful and/or satisfactory therapies especially for patients with HCC. From our understanding of both Western medicine and Chinese medicine

it could identify the targets in liver fibrosis and HCC for intervention with Chinese medicine such as bone morphogenetic protein 4 (BMP-4). BMP-4 expression was significantly increased in both liver fibrosis and HCC and saponin class of certain Chinese herbs could regulate its expression. Therefore

BMP-4 could be one of the targets for treatment of liver fibrosis and HCC from integrative medicine.

Abstract

there are no successful and/or satisfactory therapies especially for patients with HCC. From our understanding of both Western medicine and Chinese medicine

BMP-4 could be one of the targets for treatment of liver fibrosis and HCC from integrative medicine.

关键词

Liver Fibrosishepatocellular carcinomabone morphogenetic proteinIntegrative Medicine

Keywords

Liver Fibrosishepatocellular carcinomabone morphogenetic proteinIntegrative Medicine

references

Friedman SL. Liver fibrosis—from bench to bedside. J Hepatol 2003;38Suppl 1:S38–S53.

Gibbons GF, Wiggins D, Brown AM, Hebbachi AM. Synthesis and function of hepatic very-low-density lipoprotein. Biochem Soc Trans 2004;32:59–64.

Fausto N, Laird AD, Webber EM. Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. FASEB J 1995;9:1527–1536.

Jungermann K, Katz N. Functional specialization of different hepatocyte populations. Physiol Rev 1989;69:708–764.

Groothuis GM, Meijer DK. Hepatocyte heterogeneity in bile formation and hepatobiliary transport of drugs. Enzyme 1992;46:94–138.

Zhang L, Zhang QM, Wang YG, Yu DL, Zhang W. The traditional Chinese medicine pattern of the six-zang and six-fu organs can be simplified into the pattern of five-zang and one-fu organs. J Tradit Chin Med 2011;31:147–151.

Li ZG, Chen G. Comparative study on WHO Western Pacific Region and World Federation of Chinese Medicine Societies International Standard Terminologies on Traditional Medicine: six-meridian pattern identification/syndrome differentiation. J Chin Integr Med (Chin) 2011;9:1270–1276.

Mou X, Liu WH, Zhou DY, Liu YH, Hu YB, Ma GL, et al. Association of Chinese medicine constitution susceptibility to diabetic nephropathy and transforming growth factor-beta1 (T869C) gene polymorphism. Chin J Integr Med 2011;17:680–684.

Qi ZX, Chen L. Effect of Chinese drugs for promoting blood circulation and eliminating blood stasis on vascular endothelial growth factor expression in rabbits with glucocorticoid-induced ischemic necrosis of femoral head. J Tradit Chin Med 2009;29:137–140.

Friedman SL. Hepatic stellate cells. Prog Liver Dis 1996;14:101–130.

Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993;328:1592–1598.

Zamani N, Brown CW. Emerging roles for the transforming growth factor-{beta} superfamily in regulating adiposity and energy expenditure. Endocr Rev 2011;32:387–403.

Chang H, Brown CW, Matzuk MM. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 2002;23:787–823.

Attisano L, Wrana JL. Signal transduction by members of the transforming growth factor-beta superfamily. Cytokine Growth Factor Rev 1996;7:327–339.

Shen H, Huang G, Hadi M, Choy P, Zhang M, Minuk GY, et al. Transforming growth factor-beta1 downregulation of Smad1 gene expression in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2003;285:G539–G546.

Fan J, Shen H, Sun Y, Li P, Burczynski F, Namaka M, et al. Bone morphogenetic protein 4 mediates bile duct ligation induced liver fibrosis through activation of Smad1 and ERK1/2 in rat hepatic stellate cells. J Cell Physiol 2006;207:499–505.

Fan J, Shen H, Dai Q, Minuk GY, Burzynski FJ, Gong Y. Bone morphogenetic protein-4 induced rat hepatic progenitor cell (WB-F344 cell) differentiation toward hepatocyte lineage. J Cell Physiol 2009;220:72–81.

Liu P, Hu YY, Liu C, Xu LM, Liu CH, Sun KW, et al. Multicenter clinical study on Fuzhenghuayu Capsule against liver fibrosis due to chronic hepatitis B. World J Gastroenterol 2005;11:2892–2899.

Chen Y, Chen Q, Lu J, Li FH, Tao YY, Liu CH. Effects of Danggui Buxue Decoction (当归补血汤) on lipid peroxidation and MMP-2/9 activities of fibrotic liver in rats. Chin J Integr Med 2009;15:435–441.

Shen WS, Yang HZ, Hong Q, Zhang YQ, Xie HP, Bian Z. Two-year observation of the clinical efficacy in treating chronic hepatitis B patients with Ganxian Recipe and lamivudine. Chin J Integr Med 2005;11:5–10.

Wang L, Wang J, Wang BE, Xiao PG, Qiao YJ, Tan XH. Effects of herbal compound 861 on human hepatic stellate cell proliferation and activation. World J Gastroenterol 2004;10:2831–2835.

Cheung KF, Ye DW, Yang ZF, Lu L, Liu CH, Wang XL, et al. Therapeutic efficacy of traditional Chinese medicine 319 Recipe on hepatic fibrosis induced by carbon tetrachloride in rats. J Ethnopharmacol 2009;124:142–150.

Sakaida I, Matsumura Y, Akiyama S, Hayashi K, Ishige A, Okita K. Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 1998;28:298–306.

Shimizu I. Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma. J Gastroenterol Hepatol 2000;15Suppl:D84–D90.

Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, et al. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999;29:149–160.

Fan J, Li X, Li P, Li N, Wang T, Shen H, et al. Saikosaponin-d attenuates the development of liver fibrosis by preventing hepatocyte injury. Biochem Cell Biol 2007;85:189–195.

Yuspa SH, Dlugosz AA, Cheng CK, Denning MF, Tennenbaum T, Glick AB, et al. Role of oncogenes and tumor suppressor genes in multistage carcinogenesis. J Invest Dermatol 1994;103:S90–S95.

Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14:818–829.

WHO. World Health Organization Fact sheets: Cancer. 2012; Available from: http://www.who.int/mediacentre/factsheets/fs297/en/.

Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 2011;32:1122–1132.

Blonski W, Reddy KR. Hepatitis C virus infection and hepatocellular carcinoma. Clin Liver Dis 2008;12:661–674, x.

Lok AS. Hepatitis B: liver fibrosis and hepatocellular carcinoma. Gastroenterol Clin Biol 2009;33:911–915.

Cao ZY, Chen XZ, Liao LM, Peng J, Hu HX, Liu ZZ, et al. Fuzheng Yiliu Granule inhibits the growth of hepatocellular cancer by regulating immune function and inducing apoptosis in vivo and in vitro. Chin J Integr Med 2011;17:691–697.

Tian HQ, Li HL, Wang B, Liang GW, Huang XQ, Huang ZQ, et al. Treatment of middle/late stage primary hepatic carcinoma by Chinese medicine comprehensive therapy: a prospective randomized controlled study. Chin J Integr Med 2010;16:102–108.

D’Alessandro N, Poma P, Montalto G. Multifactorial nature of hepatocellular carcinoma drug resistance: could plant polyphenols be helpful? World J Gastroenterol 2007;13:2037–2043.

Ranieri G, Gadaleta-Caldarola G, Goffredo V, Patruno R, Mangia A, Rizzo A, et al. Sorafenib (BAY 43–9006) in hepatocellular carcinoma patients: from discovery to clinical development. Curr Med Chem 2012 [Epub ahead of print].

Hibasami H, Iwase H, Yoshioka K, Takahashi H. Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells. Int J Mol Med 2006;17:215–219.

Anis KV, Rajeshkumar NV, Kuttan R. Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001;53:763–768.

Sun Y, Cai TT, Shen Y, Zhou XB, Chen T, Xu Q. Si-Ni-San, a traditional Chinese prescription, and its active ingredient glycyrrhizin ameliorate experimental colitis through regulating cytokine balance. Int Immunopharmacol 2009;9:1437–1443.

Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006;44:240–251.

Shi GM, Xu Y, Fan J, Zhou J, Yang XR, Qiu SJ, et al. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol 2008;134:1155–1163.

FULL TEXT LINK

More>

浏览量

883

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Xiayuxue Decoction (下瘀血汤) attenuates hepatic stellate cell activation and sinusoidal endothelium defenestration in CCl4-induced fibrotic liver of mice

Chinese medicine education and its challenges in the United States

Search of novel model for integrative medicine

Bear bile powder (熊胆粉) induces apoptosis of human hepatocellular carcinoma cells via mitochondrion-dependent pathway

Syndrome pattern and its application in parallel randomized controlled trials